Literature DB >> 522481

Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. VIII. Expression and shedding of Fc gamma receptors on metastatic tumor cell variants.

V Schirrmacher, W Jacobs.   

Abstract

The expression of receptors for the Fc portion of IgG immunoglobin molecules was studied on tumor cell lines with high and low metastatic capacity. Two tumor cell lines from DBA/2 mice that had high metastatic activity, ESb and MDAY-D2, contained a high percentage of Fc receptor positive cells, as detected in a rosette assay with IgG antibody-coated erythrocytes (EA). In contrast, the low metastatic parental line Eb, from which ESb was derived, contained only a low percentage of EA-rosette-forming cells. ESb ascites tumor cells adapted to tissue culture in the presence of 2-mercaptoethanol (2ME) had a high expression of Fc receptors, whereas a cell line adapted to tissue culture in the absence of 2ME had a low expression of Fc receptors. "Soluble" Fc receptors were detectable by their ability to bind to EA and to cause blocking of rosette formation. They were found to be present in fluids from tumor-bearing animals, such as serum and cell-free ascites. Even animals with an ascites tumor of the low-metastatic line Eb contained "soluble" Fc receptors. The results are discussed with regard to their possible significance for tumor metastasis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 522481     DOI: 10.1002/jss.400110111

Source DB:  PubMed          Journal:  J Supramol Struct        ISSN: 0091-7419


  7 in total

1.  Antigenic variation in cancer metastasis: immune escape versus immune control.

Authors:  V Schirrmacher; M Fogel; E Russmann; K Bosslet; P Altevogt; L Beck
Journal:  Cancer Metastasis Rev       Date:  1982       Impact factor: 9.264

2.  Clonal analysis of expression of tumor-associated transplantation antigens and of metastatic capacity.

Authors:  V Schirrmacher; K Bosslet
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

Review 3.  FcR may function as a progression factor of nonlymphoid tumors.

Authors:  I P Witz; M Ran
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

4.  Determination of cell-free interleukin 2 receptor level in the serum of normal animals and of animals bearing IL-2 receptor positive tumours with high or low metastatic capacity.

Authors:  V Schirrmacher; O Josimovic-Alasevic; H Osawa; T Diamantstein
Journal:  Br J Cancer       Date:  1987-06       Impact factor: 7.640

5.  Escape of metastasizing clonal tumor cell variants from tumor-specific cytolytic T lymphocytes.

Authors:  K Bosslet; V Schirrmacher
Journal:  J Exp Med       Date:  1981-08-01       Impact factor: 14.307

6.  Acquisition of high metastatic capacity after in vitro fusion of a nonmetastatic tumor line with a bone marrow-derived macrophage.

Authors:  L Larizza; V Schirrmacher; E Pflüger
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

7.  Immunoglobulins associated with human tumours in vivo: IgG concentrations in eluates of colonic carcinomas.

Authors:  J M MacSween; S L Eastwood
Journal:  Br J Cancer       Date:  1980-10       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.